Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.

Sudden blastic transformation (SBT) has been reported in 0.5% to 2.5% of patients treated with interferon-alpha (IFN-alpha) during the first 3 years of therapy. Imatinib is now standard therapy for patients with chronic myeloid leukemia in chronic phase. We investigated the occurrence of SBT among patients treated with imatinib. Among 541 patients treated with imatinib in chronic phase, 23 developed blast phase, which was of sudden onset (ie, occurring in patients previously in complete cytogenetic remission) in 4 patients (17%; 0.7% of the total), 2 lymphoid and 2 myeloid. Patients with SBT were found to have low-risk features more often at the time of presentation and had achieved optimal response with imatinib. Three of the 4 patients underwent allogeneic stem cell transplantation and achieved a molecular remission. SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory.

[1]  Susan O'Brien,et al.  Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.

[2]  T. Vulliamy,et al.  Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib. , 2004, Leukemia research.

[3]  T. Imamura,et al.  Early blastic transformation following complete cytogenetic response in a pediatric chronic myeloid leukemia patient treated with imatinib mesylate. , 2004, Journal of pediatric hematology/oncology.

[4]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[5]  H. Kantarjian,et al.  Sudden onset of the blastic phase of chronic myelogenous leukemia , 2003, Cancer.

[6]  G. Avvisati,et al.  Clinical Observations, Interventions, and Therapeutic Trials , 2000 .

[7]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[8]  E. Canaani,et al.  Chronic myelogenous leukemia: biology and therapy. , 1993, Leukemia.

[9]  D. Swirsky,et al.  Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases , 1992, British journal of haematology.

[10]  H. Kantarjian,et al.  Advanced-phase chronic myeloid leukemia. , 2003, Seminars in hematology.

[11]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[12]  S. Bose,et al.  Lymphoid blast crisis during complete cytogenetic remission following interferon-alpha and hydroxyurea therapy. , 1997, Acta haematologica.